

**ASX RELEASE**  
**30 March 2017**

**Update regarding registration of  
Bellamy's products with China Food and Drug Administration**

Further to its ASX announcement on 28 February 2017, Bellamy's Australia Limited (Bellamy's or the Company) provides this further update regarding registration of its products with the China Food and Drug Administration (CFDA).

As previously announced, from 1 January 2018, the People's Republic of China (PRC) will require the infant formula products of the Company that are manufactured for sale in PRC (PRC products) to be registered with the CFDA.

Bellamy's confirms that following discussions with Bega, its PRC products can no longer be registered at Bega's Derrimut canning line. Bellamy's also confirms that its manufacturing contract with Bega remains in place for other products. The Company continues to review multiple alternatives in relation to obtaining CFDA registration for its PRC products.

While the Company is confident it will achieve registration of its PRC products with the CFDA, it does not anticipate that it will have registration in place by 1 January 2018. This delay is due to the time required to complete CFDA registration and additional testing of up to 6 months of the Company's PRC products at an alternate canning line.

In 1H17, Bellamy's PRC products accounted for approximately \$16 million worth of sales, comprising 14% of total sales. Bellamy's is actively pursuing strategies to mitigate the extent of any interruptions to the supply of its PRC products.

**Media inquiries, please contact:**

John Hurst  
Quay Advisers  
+61 418 708 663